Behnood Bikdeli
@bbikdeli
Followers
1K
Following
7K
Media
218
Statuses
2K
🩺investigator, #thrombosis #antithrombotic tx,🫀outcomes @BrighamWomens @harvardmed #CORE Ed @JWatch @JACCJournals @ThrombosisRese1,Alum @YaleIMed @NYPCUCVI 🎹
Boston, MA
Joined October 2019
Tune in to hear @GBarnesMD and @bbikdeli present their round-up of this year's major advances in VTE and AF management. Stay ahead in thrombosis care with insights on recent trial data and the shift towards treatment personalization #MedX #CardioTwitter
https://t.co/55Hvh8ANiI
0
3
4
New month = new edition of 🔥What's Hot in Clots🔥 from @bbikdeli Dec. highlights: • Global #VTE burden in the spotlight • Another look at #antithrombotic monotherapy • Post-MI β-blockers in normal EF • LLMs improving VTE education • Factor XI inhibitors: the story
thrombosis.org
Circulating knowledge. Saving lives. We’re fostering a growing community where patients, their advocates, and clinicians collaborate to support and advance vascular health education.
0
2
3
We need better #global concerted efforts to understand the burden of #VTE and then come up with strategies to ⬇️it. Thank you @JACCJournals @hmkyale #DrSpatz for considering our piece on the burden of #PulmonaryEmbolism and #DeepVeinThrombosis: https://t.co/x2JzdU4miQ
jacc.org
A compelling callout of the Global Burden of Disease framework for systematically undercounting venous thromboembolism and underestimating its global cardiovascular impact. https://t.co/82SAHarNmS
#JACC #GBDStudy #cvPrev #VTE #cvVTE @bbikdeli
0
3
13
🚨🚨Forgotten no more: the 🗺️burden of #Venous #Thromboembolism Neglected for too long, it’s time to recognize the global impact of #VTE and confront the key challenges through research, clinical action, and policy change #thrombosis @JACCJournals👇 https://t.co/x2JzdU4miQ
0
10
25
Extended DOAC Therapy in Provoked VTE - HI-PRO @bbikdeli Romain Didier @MarkusAtHome
https://t.co/SannI15TiM via @YouTube
0
3
7
📊 New meta-analysis in #JACC: GLP-1 RAs reduced CV death, MACE & HF risk across 99K+ patients. ✅ Consistent benefits across diabetes, obesity, CKD & HF ⚠️ ↑ GI & gallbladder events 🎯 Personalize therapy by patient profile Read more in the new issue: https://t.co/7hWeZqRHhk
2
24
81
For patients’ sake, I hope some of the XI/XIa inhibitor trials show benefit. So far, most Phase II and one Phase III studies were underwhelming. Now LIBREXIA ACS stopped: https://t.co/7tO2pJf7sv My cautionary note in @JACCJournals @Vasculearn 👇: https://t.co/27TtmHNyWO
jacc.org
0
5
21
After two years and thousands of manuscripts, I’ve learned that the real work of an editor isn’t gatekeeping — it’s partnership. My latest @JACCJournals Editor’s Page: The Partnership 🔗 https://t.co/pii9UDzvKs
#MedTwitter #AcademicMedicine #Cardiology @YaleMed @YaleSPH
7
27
135
New @CircAHA editor Brad Maron announced by @NancyatHeart #AHA2025 Congratulations! Thank you for 10 brilliant years to retiring editor in chief f Dr. Hill @josephahill
2
12
54
Very interesting results. Kudos to @CMichaelGibson et al! Will there be a return for IIb/IIIa inhibitors? 🤔 #CELEBRATE #AHA25
CELEBRATE trial: Zalunfiban, a novel platelet GPIIb/IIIa inhibitor, given subcutaneously at first medical contact significantly improved coronary patency and 30-day CV outcomes vs. placebo in STEMI patients, with no increase in severe bleeding. #AHA25 View the slides here:
0
5
19
And another 🪶in the 🧢 of @SinaRsh w a great presentation from @AHAScience funded #PE-EHR+: The potential for NLP to improve efficient patient profiling. @Vasculearn @MGBResearchNews #thrombosis
1
2
20
⭐️ @BrighamWomens @BrighamMedRes resident #NateWatson present results of a SRMA showing association between#aPL and #stroke 🧠 #AHA25 #Thrombosis @Vasculearn @APSFA
0
3
19
And @SripalBangalore sharing thoughts about ECMO and thrombectomy. #PERSEVERE is ongoing
I was discussing how we can/should do better to identify pts who need procedures. @DJC6998 Now @jaygirimd sharing insights RE thrombectomy devices.
0
3
18
I was discussing how we can/should do better to identify pts who need procedures. @DJC6998 Now @jaygirimd sharing insights RE thrombectomy devices.
Risk stratification for #PE remains a major work-in-progress, as discussed by @GregoryPiazza4 How can we do better? Clinical factors, echo, CT, blood biomarkers. Maybe all the above, just in a more sophisticated way? #AHA25 @MGBResearchNews
1
4
14
Risk stratification for #PE remains a major work-in-progress, as discussed by @GregoryPiazza4 How can we do better? Clinical factors, echo, CT, blood biomarkers. Maybe all the above, just in a more sophisticated way? #AHA25 @MGBResearchNews
0
3
19
NEJM rarely publishes meta-analysis (NEJM Evidence does), but this is a good one! @NEJM
https://t.co/FhTnIcy7YV
nejm.org
The benefit of beta-blockers after myocardial infarction in patients with a preserved left ventricular ejection fraction (LVEF) is unclear. We conducted a meta-analysis at the individual-patient le...
4
48
227
Was NI met in OPTIMA-AF? NI margin: 5% RD or RR 1.5 Expected vs observed control rate: 10% vs 5% RD: NI met RR: NI not met Because observed rate is <50% of expected rate, NI should be established for RR margin Safety advantage driven by nonmaj bleed @DFCapodanno @CMichaelGibson
3
7
21
🧪📘 Systematic review + collaborative meta-analysis of RCTs in hospitalized #COVID19 pts: 3 trials, n=3,882 statin-naive. Primary outcome = 30-day all-cause death; safety = myopathy, liver enzymes. https://t.co/YdAO49hQpF
#CVRjax @bbikdeli @AzitaTalasaz
1
2
5
Presented at #AHA25: In patients with atrial fibrillation and a drug-eluting stent placed at least 1 year earlier, monotherapy with a non–vitamin K antagonist oral anticoagulant was noninferior to combination therapy with clopidogrel for net adverse clinical events. Full ADAPT
0
117
278